WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014179341) TREATMENT WITH OMEGA-3 FATTY ACID COMPOSITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/179341    International Application No.:    PCT/US2014/035922
Publication Date: 06.11.2014 International Filing Date: 29.04.2014
IPC:
A61K 31/20 (2006.01), A61K 31/21 (2006.01), A61K 35/60 (2006.01)
Applicants: MATINAS BIOPHARMA, INC. [US/US]; 1545 Route 206, Suite 302 Bedminster, NJ 07921 (US)
Inventors: BOBOTAS, George; (US).
FAWZY, Abdel, A.; (US)
Agent: KIM, Yelee, Y.; (US)
Priority Data:
61/817,285 29.04.2013 US
Title (EN) TREATMENT WITH OMEGA-3 FATTY ACID COMPOSITIONS
(FR) TRAITEMENT PAR DES COMPOSITIONS D'ACIDE GRAS OMÉGA-3
Abstract: front page image
(EN)Fatty acid compositions comprising at least 81% omega-3-fatty acids, salts or derivatives thereof, wherein eicosapentaenoic acid (EPA; C20:5-n3) comprises at between 80% and 95% of the total fatty acids and docosahexaenoic acid (DHA; C22:6-n3) comprises between 1% and 10% of the total fatty acids, while comprising no more than 6% omega-6 fatty acids. The compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.
(FR)L'invention concerne des compositions d'acide gras comprenant au moins 81 % d'acides gras oméga-3, des sels ou des dérivés de ceux-ci, dans lesquels l'acide éicosapentaénoïque (EPA ; C20:5-n3) constitue entre 80 % et 95 % des acides gras totaux et l'acide docosahexaénoïque (DHA ; C22:6-n3) constitue entre 1 % et 10 % des acides gras totaux, tout en comprenant pas plus de 6 % d'acides gras oméga-6. Les compositions peuvent être utilisées pour le traitement ou la prophylaxie de maladies/états dyslipidémiques, cardio-vasculaires, du système nerveux central (CNS), inflammatoires et autres ou des facteurs de risque de ceux-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)